Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study

[1] Cannon CP(2004)Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 1495-1504

[2] Braunwald E(2005)Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 1425-1435

[3] McCabe CH(2019)2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Circulation 139 e1082-e1143

[4] LaRosa JC(2020)2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur Heart J 41 111-188

[5] Grundy SM(2017)Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide JAMA Cardiol 2 361-369

[6] Waters DD(2018)High-Intensity versus non-high-intensity statins in patients achieving low-density lipoprotein cholesterol goal after percutaneous coronary intervention J Am Heart Assoc 7 e009517-1022

[7] Grundy SM(2015)Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management Eur Heart J 36 1012-2564

[8] Stone NJ(2011)Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2556-1948

[9] Bailey AL(2002)Inhibition of intestinal cholesterol absorption by ezetimibe in humans Circulation 106 1943-27

[10] Mach F(2012)Ezetimibe therapy: mechanism of action and clinical update Vasc Health Risk Manag 8 415-1613

[1] Cannon CP(2004)Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 1495-1504

[2] Braunwald E(2005)Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 1425-1435

[3] McCabe CH(2019)2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Circulation 139 e1082-e1143

[4] LaRosa JC(2020)2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur Heart J 41 111-188

[5] Grundy SM(2017)Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide JAMA Cardiol 2 361-369

[6] Waters DD(2018)High-Intensity versus non-high-intensity statins in patients achieving low-density lipoprotein cholesterol goal after percutaneous coronary intervention J Am Heart Assoc 7 e009517-1022

[7] Grundy SM(2015)Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management Eur Heart J 36 1012-2564

[8] Stone NJ(2011)Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2556-1948

[9] Bailey AL(2002)Inhibition of intestinal cholesterol absorption by ezetimibe in humans Circulation 106 1943-27

[10] Mach F(2012)Ezetimibe therapy: mechanism of action and clinical update Vasc Health Risk Manag 8 415-1613